Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines (Q34229091)

31 July 2017

title

Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines (English)

1 reference

31 July 2017

1 reference

1 reference

Coates T

1

1 reference

31 July 2017

Wilson R

2

1 reference

31 July 2017

Patrick G

3

1 reference

31 July 2017

André F

4

1 reference

31 July 2017

Watson V

5

1 reference

31 July 2017

publication date

1 March 2001

1 reference

31 July 2017

published in

Clinical Therapeutics

1 reference

31 July 2017

volume

23

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

392-403

1 reference

Global programme for control of hepatitis B infection

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980044-8

7 January 2021

Over a decade of experience with a yeast recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980044-8

7 January 2021

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980044-8

7 January 2021

Status of hepatitis B immunization programmes in 1998

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980044-8

7 January 2021

Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980044-8

7 January 2021

Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980044-8

7 January 2021

Are booster immunisations needed for lifelong hepatitis B immunity?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980044-8

7 January 2021

Protective efficacy of a recombinant DNA vaccine against hepatitis B in male homosexuals: results at 36 months

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980044-8

7 January 2021

The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive-hepatitis B surface antigen carrier mothers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980044-8

7 January 2021

Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980044-8

7 January 2021

A follow-up study of combined vaccination with plasma-derived and recombinant hepatitis B vaccines in infants

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980044-8

7 January 2021

Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980044-8

7 January 2021

Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980044-8

7 January 2021

Active immunization of homosexual men using a recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980044-8

7 January 2021

Prediction of response to hepatitis B vaccine in health care workers: whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980044-8

7 January 2021

Hepatitis-B Vaccination in the Elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980044-8

7 January 2021

Comparative immunogenicity under field conditions of two recombinant hepatitis B vaccines in 8-10-year-old children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980044-8

7 January 2021

10.1016/S0149-2918(01)80044-8

Identifiers

DOI

1 reference

31 July 2017

1 reference